Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medistim ASAOSTO:MEDIO 98 EV-to-EBITDA is 20.16 as of Aug. 25, 2026, which is 5% below its 10-year median of 21.24. GuruFocus rates OSTO:MEDIO with a GF Score™ of 98/100 and a GF Value™ of kr249.16 (Fairly Valued). The stock has 4 warning signs investors should review. Among 516 Medical Devices & Instruments companies, Medistim ASA ranks worse than 67.83% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Medistim ASA's enterprise value is kr4,615.1 Mil.
Medistim ASA's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was kr228.9 Mil. Therefore, Medistim ASA's EV-to-EBITDA for today is 20.16.
The historical rank and industry rank for Medistim ASA's EV-to-EBITDA or its related term are showing as below:
OSTO:MEDIO'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 13.59 Med: 21.24 Max: 53.31
Current: 20.16
During the past 13 years, the highest EV-to-EBITDA of Medistim ASA was 53.31. The lowest was 13.59. And the median was 21.24.
OSTO:MEDIO's EV-to-EBITDA is ranked worse than 67.83% of 516
companies
in the Medical Devices & Instruments industry
Industry Median: 14.67
vs OSTO:MEDIO: 20.16
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Medistim ASA's PE Ratio (TTM) for today is calculated as:
Medistim ASA's share price for today is kr250.00.
Medistim ASA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr9.030.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Medistim ASA's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:MEDIO vs ABT, SYK, MDT: EV-to-EBITDA Comparison
For the Medical Devices subindustry, Medistim ASA's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medistim ASA EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medistim ASA's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Medistim ASA's EV-to-EBITDA falls into.
Medistim ASA's current Enterprise Value is kr4,615.1 Mil.
Medistim ASA's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr228.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medistim ASA (OSTO:MEDIO) has a EV-to-EBITDA of 20.16 as of Aug. 25, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Medistim ASA. This is near median its historical median of 21.24. Over the past decade, Medistim ASA's EV-to-EBITDA has ranged from 13.59 to 53.31. According to the industry distribution chart, Medistim ASA ranks #350 out of 516 companies in the Medical Devices & Instruments industry, placing it in the top 67.8%.
Is Medistim ASA's EV-to-EBITDA too high?
Medistim ASA's current EV-to-EBITDA of 20.16 is near median its 10-year median of 21.24. Over the past 10 years, this metric has ranged from a low of 13.59 to a high of 53.31. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.67. Medistim ASA's value of 20.16 is 37.4% above this industry median. Based on the distribution chart, Medistim ASA ranks #350 out of 516 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Medistim ASA has a GF Score™ of 98/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medistim ASA's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medistim ASA ranks #350 out of 516 companies for EV-to-EBITDA. This places Medistim ASA in the lower half of its industry. The industry median EV-to-EBITDA is 14.67. Medistim ASA's value of 20.16 is 37.4% above this benchmark. Historically, Medistim ASA's own EV-to-EBITDA has ranged from 13.59 to 53.31 over the past decade. While the company's 10-year median is 21.24 vs. the industry median of 14.67, Medistim ASA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.67, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medistim ASA's current EV-to-EBITDA of 20.16 is 37.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Medistim ASA. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medistim ASA's current EV-to-EBITDA is 20.16, which is near median its own 10-year median of 21.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medistim ASA stock overvalued right now?
Based on GuruFocus' analysis, Medistim ASA (OSTO:MEDIO) is currently considered Fairly Valued. The stock's GF Value™ is kr249.16, compared to a current price of kr250.00 — trading 0.3% above its estimated fair value. The current EV-to-EBITDA is 20.16, which is near median its 10-year median of 21.24 and 37.4% above the Medical Devices & Instruments industry median of 14.67. Medistim ASA's overall GF Score™ is 98/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Medistim ASA (OSTO:MEDIO), the current EV-to-EBITDA is 20.16 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medistim ASA (OSTO:MEDIO) Overvalued in 2026?
Based on GuruFocus' analysis, Medistim ASA stock appears to be overvalued.
The current stock price of kr250.00 is trading 0.3% above its estimated GF Value™ of kr249.16.
GuruFocus considers Medistim ASA to be Fairly Valued.
Key valuation signals for OSTO:MEDIO:
EV-to-EBITDA: 20.16 (near median its 10-year median of 21.24)
GF Value™: kr249.16 vs. price of kr250.00 (0.3% above fair value)
Industry Position: 37.4% above the Medical Devices & Instruments median (#350 of 516)
No single metric tells the full story. See the OSTO:MEDIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medistim ASA is a medical device company. It is engaged in researching, developing, producing, distributing, and sales of medical equipment through its own business or participation in other companies, as well as related activities. The company's business is focused on cardiac and vascular surgery. The group operates in the USA, Europe, China, and the Rest of the World. The main divisions are sale of own products and sale of third-party products. Sale of own products has two business models, the capital model and the lease model. Third-party products segment sells medical devices from third party manufacturers in Norway, Sweden and Denmark. Key revenue is generated from Own Products segment.
98GF Score
Get the complete analysis for OSTO:MEDIO
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:MEDIO has been successfully added to your 
